 | • レポートコード：MRC2304I0156 • 出版社/出版日：Persistence Market Research / 2023年1月10日 • レポート形態：英文、PDF、250ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Site Licence | ￥1,140,000 (USD7,600) | ▷ お問い合わせ |
| Enterprisewide | ￥1,590,000 (USD10,600) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Persistence Market Research社の本調査資料では、世界の抗ウイルス薬市場について調査・分析を行い、市場の現状と今後の展望を整理しています。本書は、エグゼクティブサマリー、市場概要、市場リスク・動向評価、市場背景、主要成功要因、需要分析・予測、価値分析・予測、薬剤クラス別（DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、ノイラミニダーゼ阻害剤、プロテアーゼ阻害剤、その他）分析、種類別（ブランド、ジェネリック）分析、用途別（HIV、肝炎、ヘルペス、インフルエンザ、その他）分析、地域別（北米、中南米、ヨーロッパ、アジア太平洋、中東・アフリカ）分析、市場構造分析、競争分析、仮定、調査手法など、以下の構成で掲載しています。また、Gilead Sciences Inc、GlaxoSmithKline plc、F. Hoffmann-La Roche Ltd、Merck & Co. Inc、AbbVie、Johnson & Johnson Services, Inc.、Bristol-Myers Squibb Company、Cipla Inc.、Aurobindo Pharma、Dr. Reddy’s Laboratories Ltd.などの企業情報が含まれています。 ・エグゼクティブサマリー ・市場概要 ・市場リスク・動向評価 ・市場背景 ・主要成功要因 ・需要分析・予測 ・価値分析・予測 ・世界の抗ウイルス薬市場規模：薬剤クラス別 - DNAポリメラーゼ阻害剤の市場規模 - 逆転写酵素阻害剤の市場規模 - ノイラミニダーゼ阻害剤の市場規模 - プロテアーゼ阻害の市場規模 - その他薬剤クラスの市場規模 ・世界の抗ウイルス薬市場規模：種類別 - ブランドにおける市場規模 - ジェネリックにおける市場規模 ・世界の抗ウイルス薬市場規模：用途別 - HIVにおける市場規模 - 肝炎における市場規模 - ヘルペスにおける市場規模 - インフルエンザにおける市場規模 - その他用途における市場規模 ・世界の抗ウイルス薬市場規模：地域別 - 北米の抗ウイルス薬市場規模 - 中南米の抗ウイルス薬市場規模 - ヨーロッパの抗ウイルス薬市場規模 - アジア太平洋の抗ウイルス薬市場規模 - 中東・アフリカの抗ウイルス薬市場規模 ・市場構造分析 ・競争分析 ・仮定 ・調査手法 |
Global Antiviral Drugs Market – Scope of Report
A recent study by Persistence Market Research on the?Global Antiviral Drugs market offers a 10-year forecast for 2022 to 2032. The study analyzes crucial trends that are currently determining the growth of the market. This report explicates on vital dynamics, such as the drivers, restraints, and opportunities for key market players along with key stakeholders as well as emerging players associated with offering?Global Antiviral Drugs products
The study also provides the dynamics responsible for influencing the future status of the?Global Antiviral Drugs market over the forecast period. A detailed assessment of value chain analysis, business execution, and segment wise analysis across regional markets has been covered in the report.
A list of prominent companies operating in the?Global Antiviral Drugs market, along with their product portfolios, key strategies and SWOT analysis, enhances the reliability of this comprehensive research study.
Report Summary
The study offers comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales of?Global Antiviral Drugs across the globe.
A comprehensive estimate on the market has been provided through an optimistic as well as a conservative scenario, taking into account the product and services of Global Antiviral Drugs during the forecast period. Price point comparison by region with global average price is also considered in the study.
Analysis on Market Size Evaluation
The market has been analyzed for each segment in terms of value (US$ Mn).
Estimates at global and regional levels for?Global Antiviral Drugs and the Global Antiviral Drugs market are available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent market segments, along with market attractiveness evaluation, has been incorporated in the report. Furthermore, absolute dollar?opportunity analysis of all the segments adds prominence to the report. Absolute dollar opportunity plays a crucial role in assessing the level of opportunity that a manufacturer/distributor can look to achieve, along with identifying potential resources, considering the sales and services perspective in the global?Antiviral Drugs market.
Inspected Assessment on Regional Segments
Key sections have been elaborated in the report, which have helped deliver projections on regional markets. These chapters include regional macros (political, economic, and business environment outlook), which are expected to have a momentous influence on the growth of the?Global Antiviral Drugs market during the forecast period.
Country-specific valuation on demand for?Global Antiviral Drugs has been offered for each region, along with market scope estimates and forecasts, price index, and impact analysis of the dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
In-depth Analysis on Competition
The report sheds light on leading players of?Global Antiviral Drugs markets along with their detailed profiles. Essential and up-to-date data related to market performers who are principally engaged in offering?Global Antiviral Drugs has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which include essentials such as product portfolios and key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting the market status, and predicting the competition level in the Global Antiviral Drugs Market.
レポート目次1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Persistence Market Research Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Antiviral Drugs
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Million)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background
4.1. Antiviral Drugs Market, by Key Countries
4.2. Antiviral Drugs Market Opportunity Assessment (US$ Million)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors – Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Growth in Automation, By Country
4.5.3. Patch Management Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Patch Management Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Antiviral Drugs Market Demand Analysis 2018-2022 and Forecast, 2023-2033
6.1. Historical Market Analysis, 2018-2022
6.2. Current and Future Market Projections, 2023-2033
6.3. Y-o-Y Growth Trend Analysis
7. Global Antiviral Drugs Market Value Analysis 2018-2022 and Forecast, 2023-2033
7.1. Historical Market Value (US$ Million) Analysis, 2018-2022
7.2. Current and Future Market Value (US$ Million) Projections, 2023-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Class
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018-2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023-2033
8.3.1. DNA Polymerase Inhibitors
8.3.2. Reverse Transcriptase Inhibitors
8.3.3. Neuraminidase Inhibitors
8.3.4. Protease Inhibitors
8.3.5. others
8.4. Market Attractiveness Analysis By Drug Class
9. Global Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033, By Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Type, 2018-2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Type, 2023-2033
9.3.1. Branded
9.3.2. Generics
9.4. Market Attractiveness Analysis By Type
10. Global Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Application, 2018-2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023-2033
10.3.1. HIV
10.3.2. Hepatitis
10.3.3. Herpes
10.3.4. Influenza
10.3.5. Other Applications
10.4. Market Attractiveness Analysis By Application
11. Global Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033, By Region
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Region, 2018-2022
11.3. Current Market Size (US$ Million) & Analysis and Forecast By Region, 2023-2033
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. Asia Pacific
11.3.5. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
12.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2023-2033
12.4.1. By Country
12.4.1.1. U.S.
12.4.1.2. Canada
12.4.1.3. Rest of North America
12.4.2. By Drug Class
12.4.3. By Application
12.4.4. By Type
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Drug Class
12.5.3. By Application
12.5.4. By Type
13. Latin America Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
13.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2023-2033
13.4.1. By Country
13.4.1.1. Brazil
13.4.1.2. Mexico
13.4.1.3. Rest of Latin America
13.4.2. By Drug Class
13.4.3. By Application
13.4.4. By Type
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Drug Class
13.5.3. By Application
13.5.4. By Type
14. Europe Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
14.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2023-2033
14.4.1. By Country
14.4.1.1. Germany
14.4.1.2. France
14.4.1.3. U.K.
14.4.1.4. Italy
14.4.1.5. Spain
14.4.1.6. Russia
14.4.1.7. Rest of Europe
14.4.2. By Drug Class
14.4.3. By Application
14.4.4. By Type
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Drug Class
14.5.3. By Application
14.5.4. By Type
15. Asia Pacific Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
15.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2023-2033
15.4.1. By Country
15.4.1.1. China
15.4.1.2. Japan
15.4.1.3. South Korea
15.4.1.4. Australia
15.4.1.5. India
15.4.1.6. Rest of Asia Pacific
15.4.2. By Drug Class
15.4.3. By Application
15.4.4. By Type
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Drug Class
15.5.3. By Application
15.5.4. By Type
16. Middle East and Africa Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
16.1. Introduction
16.2. Pricing Analysis
16.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2018-2022
16.4. Market Size (US$ Million) & Forecast By Market Taxonomy, 2023-2033
16.4.1. By Country
16.4.1.1. Saudi Arabia
16.4.1.2. South Africa
16.4.1.3. Israel
16.4.1.4. Rest of Middle East and Africa
16.4.2. By Drug Class
16.4.3. By Application
16.4.4. By Type
16.5. Market Attractiveness Analysis
16.5.1. By Country
16.5.2. By Drug Class
16.5.3. By Application
16.5.4. By Type
17. Key Countries Antiviral Drugs Market Analysis 2018-2022 and Forecast 2023-2033
17.1. Introduction
17.1.1. Market Value Proportion Analysis, By Key Countries
17.1.2. Global Vs. Country Growth Comparison
17.2. US Antiviral Drugs Market Analysis
17.2.1. Value Proportion Analysis by Market Taxonomy
17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.2.2.1. By Drug Class
17.2.2.2. By Application
17.2.2.3. By Type
17.3. Canada Antiviral Drugs Market Analysis
17.3.1. Value Proportion Analysis by Market Taxonomy
17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.3.2.1. By Drug Class
17.3.2.2. By Application
17.3.2.3. By Type
17.4. Mexico Antiviral Drugs Market Analysis
17.4.1. Value Proportion Analysis by Market Taxonomy
17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.4.2.1. By Drug Class
17.4.2.2. By Application
17.4.2.3. By Type
17.5. Brazil Antiviral Drugs Market Analysis
17.5.1. Value Proportion Analysis by Market Taxonomy
17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.5.2.1. By Drug Class
17.5.2.2. By Application
17.5.2.3. By Type
17.6. Germany Antiviral Drugs Market Analysis
17.6.1. Value Proportion Analysis by Market Taxonomy
17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.6.2.1. By Drug Class
17.6.2.2. By Application
17.6.2.3. By Type
17.7. France Antiviral Drugs Market Analysis
17.7.1. Value Proportion Analysis by Market Taxonomy
17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.7.2.1. By Drug Class
17.7.2.2. By Application
17.7.2.3. By Type
17.8. Italy Antiviral Drugs Market Analysis
17.8.1. Value Proportion Analysis by Market Taxonomy
17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.8.2.1. By Drug Class
17.8.2.2. By Application
17.8.2.3. By Type
17.9. Spain Antiviral Drugs Market Analysis
17.9.1. Value Proportion Analysis by Market Taxonomy
17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.9.2.1. By Drug Class
17.9.2.2. By Application
17.9.2.3. By Type
17.10. UK Antiviral Drugs Market Analysis
17.10.1. Value Proportion Analysis by Market Taxonomy
17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.10.2.1. By Drug Class
17.10.2.2. By Application
17.10.2.3. By Type
17.11. Russia Antiviral Drugs Market Analysis
17.11.1. Value Proportion Analysis by Market Taxonomy
17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.11.2.1. By Drug Class
17.11.2.2. By Application
17.11.2.3. By Type
17.12. China Antiviral Drugs Market Analysis
17.12.1. Value Proportion Analysis by Market Taxonomy
17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.12.2.1. By Drug Class
17.12.2.2. By Application
17.12.2.3. By Type
17.13. Japan Antiviral Drugs Market Analysis
17.13.1. Value Proportion Analysis by Market Taxonomy
17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.13.2.1. By Drug Class
17.13.2.2. By Application
17.13.2.3. By Type
17.14. South Korea Antiviral Drugs Market Analysis
17.14.1. Value Proportion Analysis by Market Taxonomy
17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.14.2.1. By Drug Class
17.14.2.2. By Application
17.14.2.3. By Type
17.15. Saudi Arabia Antiviral Drugs Market Analysis
17.15.1. Value Proportion Analysis by Market Taxonomy
17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.15.2.1. By Drug Class
17.15.2.2. By Application
17.15.2.3. By Type
17.16. South Africa Antiviral Drugs Market Analysis
17.16.1. Value Proportion Analysis by Market Taxonomy
17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.16.2.1. By Drug Class
17.16.2.2. By Application
17.16.2.3. By Type
17.17. Israel Antiviral Drugs Market Analysis
17.17.1. Value Proportion Analysis by Market Taxonomy
17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2018-2033
17.17.2.1. By Drug Class
17.17.2.2. By Application
17.17.2.3. By Type
17.17.3. Competition Landscape and Player Concentration in the Country
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Concentration
18.3. Market Share Analysis of Top Players
18.4. Market Presence Analysis
18.4.1. By Regional footprint of Players
18.4.2. Product footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. Gilead Sciences Inc
19.3.1.1. Overview
19.3.1.2. Product Portfolio
19.3.1.3. Sales Footprint
19.3.1.4. Strategy Overview
19.3.2. GlaxoSmithKline plc
19.3.2.1. Overview
19.3.2.2. Product Portfolio
19.3.2.3. Sales Footprint
19.3.2.4. Strategy Overview
19.3.3. F. Hoffmann-La Roche Ltd
19.3.3.1. Overview
19.3.3.2. Product Portfolio
19.3.3.3. Sales Footprint
19.3.3.4. Strategy Overview
19.3.4. Merck & Co. Inc
19.3.4.1. Overview
19.3.4.2. Product Portfolio
19.3.4.3. Sales Footprint
19.3.4.4. Strategy Overview
19.3.5. AbbVie
19.3.5.1. Overview
19.3.5.2. Product Portfolio
19.3.5.3. Sales Footprint
19.3.5.4. Strategy Overview
19.3.6. Johnson & Johnson Services, Inc.
19.3.6.1. Overview
19.3.6.2. Product Portfolio
19.3.6.3. Sales Footprint
19.3.6.4. Strategy Overview
19.3.7. Bristol-Myers Squibb Company
19.3.7.1. Overview
19.3.7.2. Product Portfolio
19.3.7.3. Sales Footprint
19.3.7.4. Strategy Overview
19.3.8. Cipla Inc.
19.3.8.1. Overview
19.3.8.2. Product Portfolio
19.3.8.3. Sales Footprint
19.3.8.4. Strategy Overview
19.3.9. Aurobindo Pharma
19.3.9.1. Overview
19.3.9.2. Product Portfolio
19.3.9.3. Sales Footprint
19.3.9.4. Strategy Overview
19.3.10. Dr. Reddy’s Laboratories Ltd.
19.3.10.1. Overview
19.3.10.2. Product Portfolio
19.3.10.3. Sales Footprint
19.3.10.4. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology